Sol Gel Technologies Ltd (SLGL) - Net Assets

Latest as of December 2025: $22.81 Million USD

Based on the latest financial reports, Sol Gel Technologies Ltd (SLGL) has net assets worth $22.81 Million USD as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($29.92 Million) and total liabilities ($7.11 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check asset resilience ratio of Sol Gel Technologies Ltd to evaluate the company's liquid asset resilience ratio.

Key Net Assets Metrics

Metric Value
Current Net Assets $22.81 Million
% of Total Assets 76.25%
Annual Growth Rate N/A
5-Year Change -58.97%
10-Year Change N/A
Growth Volatility 11.83

Sol Gel Technologies Ltd - Net Assets Trend (2014–2025)

This chart illustrates how Sol Gel Technologies Ltd's net assets have evolved over time, based on quarterly financial data. Also explore Sol Gel Technologies Ltd balance sheet assets for the complete picture of this company's asset base.

Annual Net Assets for Sol Gel Technologies Ltd (2014–2025)

The table below shows the annual net assets of Sol Gel Technologies Ltd from 2014 to 2025. For live valuation and market cap data, see Sol Gel Technologies Ltd stock valuation.

Year Net Assets Change
2025-12-31 $22.81 Million -20.93%
2024-12-31 $28.85 Million -25.34%
2023-12-31 $38.64 Million -8.45%
2022-12-31 $42.21 Million -24.07%
2021-12-31 $55.59 Million +9.33%
2020-12-31 $50.85 Million -3.08%
2019-12-31 $52.47 Million -17.91%
2018-12-31 $63.91 Million +221.27%
2017-12-31 $-52.70 Million -68.17%
2016-12-31 $-31.34 Million -172.07%
2015-12-31 $-11.52 Million -406.29%
2014-12-31 $-2.27 Million --

Equity Component Analysis

This analysis shows how different components contribute to Sol Gel Technologies Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have decreased by 20374800000.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (December 2025)

Component Amount Percentage
Common Stock $774.00K 3.39%
Other Components $259.05 Million 1135.62%
Total Equity $22.81 Million 100.00%

Sol Gel Technologies Ltd Competitors by Market Cap

The table below lists competitors of Sol Gel Technologies Ltd ranked by their market capitalization.

Company Market Cap
Hold-Key Electric Wire & Cable Co Ltd
TW:1618
$233.73 Million
Libra Insurance Company Ltd
TA:LBRA
$233.99 Million
Eisen- und Hüttenwerke AG
F:EIS
$234.08 Million
Grupa Azoty Zaklady Azotowe Pulawy SA
WAR:ZAP
$234.10 Million
Kaldalón hf.
IC:KALD
$233.70 Million
Síminn hf
IC:SIMINN
$233.59 Million
Banque Cantonale Du Jura SA
SW:BCJ
$233.49 Million
Eaton Vance California MBF
NYSE MKT:EVM
$233.41 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Sol Gel Technologies Ltd's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2024 to 2025, total equity changed from 28,850,000 to 22,811,000, a change of -6,039,000 (-20.9%).
  • Net loss of 6,127,000 reduced equity.

Equity Change Factors (2024 to 2025)

Factor Impact Contribution
Net Income $-6.13 Million -26.86%
Other Changes $88.00K +0.39%
Total Change $- -20.93%

Book Value vs Market Value Analysis

This analysis compares Sol Gel Technologies Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 9.23x
  • The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2014-12-31 $-1.11 $75.61 x
2015-12-31 $-0.98 $75.61 x
2016-12-31 $-2.67 $75.61 x
2017-12-31 $-2.93 $75.61 x
2018-12-31 $3.58 $75.61 x
2019-12-31 $2.69 $75.61 x
2020-12-31 $2.25 $75.61 x
2021-12-31 $2.36 $75.61 x
2022-12-31 $1.83 $75.61 x
2023-12-31 $1.43 $75.61 x
2024-12-31 $1.04 $75.61 x
2025-12-31 $8.19 $75.61 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Sol Gel Technologies Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): -26.86%
  • The company may be facing challenges in efficiently utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: -31.60%
  • • Asset Turnover: 0.65x
  • • Equity Multiplier: 1.31x
  • Recent ROE (-26.86%) is below the historical average (-26.23%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2014 0.00% 0.00% 0.00x 0.00x $-4.55 Million
2015 0.00% 0.00% 0.00x 0.00x $-8.51 Million
2016 0.00% 0.00% 0.00x 0.00x $-17.64 Million
2017 0.00% -18142.53% 0.01x 0.00x $-26.30 Million
2018 -50.39% -24963.57% 0.00x 1.09x $-38.59 Million
2019 -46.91% -107.44% 0.37x 1.17x $-29.86 Million
2020 -53.89% -312.40% 0.15x 1.16x $-32.49 Million
2021 5.79% 10.30% 0.45x 1.24x $-2.34 Million
2022 -35.35% -384.32% 0.08x 1.10x $-19.14 Million
2023 -70.48% -1752.77% 0.03x 1.17x $-31.10 Million
2024 -36.67% -91.70% 0.32x 1.24x $-13.46 Million
2025 -26.86% -31.60% 0.65x 1.31x $-8.41 Million

Industry Comparison

This section compares Sol Gel Technologies Ltd's net assets metrics with peer companies in the Biotechnology industry.

Industry Context

  • Industry: Biotechnology
  • Average net assets among peers: $44,828,400
  • Average return on equity (ROE) among peers: -124.18%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Sol Gel Technologies Ltd (SLGL) $22.81 Million 0.00% 0.31x $233.72 Million
Aardvark Therapeutics, Inc. Common Stock (AARD) $-54.64 Million 0.00% 0.00x $118.88 Million
Abcellera Biologics Inc (ABCL) $10.25 Million -21.57% 1.29x $1.07 Billion
Abeona Therapeutics Inc (ABEO) $3.60 Million -91.89% 0.28x $292.09 Million
Acumen Pharmaceuticals Inc (ABOS) $266.97 Million -19.62% 0.16x $171.87 Million
Abpro Holdings, Inc. (ABP) $3.07 Million -479.81% 1.57x $448.19K
Absci Corp (ABSI) $67.00 Million -21.42% 0.32x $345.85 Million
Arbutus Biopharma Corp (ABUS) $88.00 Million -44.09% 0.34x $840.56 Million
ABVC Biopharma Inc (ABVC) $80.00K -31.70% 0.38x $26.41 Million
Abivax SA American Depositary Shares (ABVX) $40.58 Million -434.26% 4.06x $9.33 Billion
ACADIA Pharmaceuticals Inc (ACAD) $23.36 Million -97.44% 0.37x $3.74 Billion

About Sol Gel Technologies Ltd

NASDAQ:SLGL USA Biotechnology
Market Cap
$245.37 Million
Market Cap Rank
#15948 Global
#3609 in USA
Share Price
$75.61
Change (1 day)
+2.12%
52-Week Range
$4.42 - $97.97
All Time High
$97.97
About

Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel, China, Switzerland, Canada, the United States and internationally. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treat… Read more